Phase I Clinical Study to Evaluate the Tolerability and Pharmacokinetics of TQB3811 Tablets in Patients With Advanced Malignant Tumors
Latest Information Update: 06 Dec 2023
At a glance
- Drugs TQB 3811 (Primary)
- Indications Solid tumours
- Focus Adverse reactions
- Sponsors Chia Tai Tianqing Pharmaceutical Group
Most Recent Events
- 02 Dec 2021 Status changed from not yet recruiting to recruiting.
- 21 Sep 2021 New trial record